BioWa announces licensing of BioWa`s POTELLIGENT(R) Technology

The agreement grants GSK non-exclusive rights to research and develop antibodies based on POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, and license fees.

Other details of the agreement are not disclosed.

"GSK has long time remained a strong leader in the pharmaceutical industry for both innovation and marketing," said Dr. Masamichi Koike, President and CEO of BioWa.

"With the breadth and depth of GSK research, we are pleased to partner with a company that has large capabilities in all sectors of research.

This collaboration will fulfill BioWa's mission to create benefit of POTELLIGENT(R)Technology to patients as quickly as possible."